We are live on ! Find out more

Pfizer

PFE

Market cap $143B

Positive

Neutral

Negative

Sentiment 3-Months

Positive 57.4%

Neutral 30.2%

Negative 12.3%

The Motley Fool

Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?

Pfizer is one of the world's largest drug makers. The company is facing typical industry headwinds as it seeks new drugs to replace older ones.

Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff?

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

U.S. drugmaker Pfizer has temporarily discontinued Premarin vaginal cream in India, shrinking estrogen therapy options for millions of women experiencing menopause-related symptoms in the country.

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Zacks Investment Research

Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?

PFE trades below key moving averages as investors weigh fading COVID sales against pipeline growth, acquisitions and a low valuation with a high dividend.

Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?

24/7 Wall Street

Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike.

Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King

24/7 Wall Street

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price target of $28.79, which represents implied upside of almost 19%.

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

24/7 Wall Street

Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen

Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.

Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen

Zacks Investment Research

Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results

PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.

Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results

The Motley Fool

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

Pfizer's yield has fluctuated over the years due to its volatile share price. Its recent earnings numbers suggest the dividend is safe, but there isn't a huge buffer.

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

The Motley Fool

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

Zacks Investment Research

Pfizer (PFE) Advances While Market Declines: Some Information for Investors

In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day.

Pfizer (PFE) Advances While Market Declines: Some Information for Investors

See News Rankings